Stock comparison
BioMarin Pharmaceutical
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMRN
BioMarin Pharmaceutical
Market cap
$10.45B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMRN | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 58D | 65C | GMAB |
| Benjamin Graham | 57D | 64C | GMAB |
| Philip Fisher | 55C | 48D | BMRN |
| Peter Lynch | 47D | 25F | BMRN |
| Joel Greenblatt | 28F | 76B | GMAB |
| Charlie Munger | 45D | 68C | GMAB |
| Terry Smith | 52D | 71C | GMAB |
Side-by-side metrics
| Metric | BMRN | GMAB |
|---|---|---|
| Market cap | $10.45B | $16.5B |
| P/E (TTM) | 38.7x | 6.2x |
| EV/EBIT | 18.1x | 12.0x |
| ROIC (TTM) | 3.92% | 43.78% |
| Gross margin | 75.93% | 93.88% |
| Net margin | 8.29% | 18.23% |
| Revenue CAGR 5y | 14.93% | -18.45% |
| EPS CAGR 5y | 2.29% | -23.48% |
| Debt / Equity | 0.2x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMRN leads on
- Revenue CAGR 5y14.93%vs -18.45%+181%
- EPS CAGR 5y2.29%vs -23.48%+110%
GMAB leads on
- ROIC (TTM)43.78%vs 3.92%+91%
- P/E (TTM)6.2xvs 38.7x+84%
- Debt / Equity0.1xvs 0.2x+68%
- Net margin18.23%vs 8.29%+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.